Why the study?
Pediatric heart failure has high morbidity and mortality with etiologies, physiology, and treatments distinct from adults, while new drugs and therapeutic strategies have recently emerged to enable individualized treatment.
This review summarizes new pharmacological and non-pharmacological therapeutic strategies for managing pediatric heart failure.
Pediatric heart failure (HF) is an important clinical condition with high morbidity and mortality. Compared to adults, pediatric HF shows different etiologies characterized by different physiology, a different clinical course, and deeply different therapeutic approaches. In the last few years, new drugs have been developed and new therapeutic strategies have been proposed with the goal of identifying an individualized treatment regimen. The aim of this article is to review the new potential drugs and non-pharmacological therapies for pediatric heart failure in children.
No takes yet. Share an insight, caveat, or question.
Castaldi et al. (2023) conducted a review in Pediatric heart failure. Pharmacological and non-pharmacological therapies was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: